Spruce Biosciences
SPRB
50 hedge funds and large institutions have $79M invested in Spruce Biosciences in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
16% more funds holding
Funds holding: 43 → 50 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less capital invested
Capital invested by funds: $118M → $79M (-$39.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.37M |
| 2 |
Goldman Sachs
New York
|
+$864K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$833K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$285K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.2M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.62M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.32M |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$382K |
| 5 |
Morgan Stanley
New York
|
-$252K |
SPRB Hedge Fund Activity: Q4 2021 in Review
50 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2021, worth a combined $79M — down 33% from $118M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SPRB positions and 10 closed out — a net gain of 7 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $4.37M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.2M sold.
- 50 institutional investors held Spruce Biosciences (SPRB) as of Q4 2021, up from 43 in Q3 2021.
- Funds reported $79M of Spruce Biosciences stock for Q4 2021, down 33% quarter-over-quarter.
- 17 funds opened new Spruce Biosciences positions in Q4 2021 and 10 closed out, a net change of +7 holders.
- The largest Spruce Biosciences buyer in Q4 2021 was Logos Global Management, an estimated $4.37M added.
- The largest Spruce Biosciences seller in Q4 2021 was Deerfield Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2021.